Could a preventive ablation during flutter treatment ward off future heart trouble?
NCT ID NCT07649603
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a preventive procedure called pulmonary vein isolation (PVI) to the standard ablation for typical atrial flutter can reduce the risk of heart-related hospital visits, stroke, or death. The trial enrolls adults aged 55 and older with an enlarged left atrium and no prior atrial fibrillation. Participants are randomly assigned to receive either standard ablation alone or standard ablation plus PVI, and are followed for several years to compare outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- catheter ablation (CTI ablation plus pulmonary vein isolation)
- What this could lead to
- If successful, this approach could become a standard preventive step during atrial flutter ablation, lowering the chance of future atrial fibrillation and related complications.
- What could go wrong
- This is a mid-stage trial, and the added procedure carries risks like bleeding, infection, or heart rhythm disturbances. It may not reduce events as hoped, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FLUTTER TYPICAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.